Modeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection
Authors:
Open Access
- 6 August 2025
- journal article
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70521
Abstract
Understanding the dynamics of SARS‐CoV‐2 antibody levels post‐booster vaccination is important to inform their durations of protection. Longitudinal antibody data was collected on the day of booster vaccination, as well as 28, 180, and 360 days after. Using nonlinear mixed effects models, we mapped the kinetics of binding IgA and IgG against wild‐type (WT) and Omicron BA.1 spike proteins. Furthermore, we analyzed the association between antibody levels and risk of SARS‐CoV‐2 vaccine breakthrough infection through survival analyzes, and predicted durations of protection against infection. We found that the antibody response waned more rapidly following the Pfizer/BioNTech BNT162b2 booster compared to the Moderna mRNA‐1273 booster. However, individuals boosted with the Pfizer vaccine exhibited a steeper rebound in antibody levels after infection. Faster postinfection antibody growth rates were observed in the elderly, females, and those with late infections. High antibody levels for WT IgG and BA.1 IgA at day 28 post‐booster were associated with reduced infection risk; hazard ratios were 0.47 (95% CI [0.22, 0.98]) and 0.36 (95% CI [0.17, 0.78]), respectively, compared to low levels. Time‐varying antibody levels showed better survival model fits. At medium COVID‐19 case incidence (621 cases per million per day), a binding BA.1 IgA response of at least 20% is needed to sustain 80% protection against infection over 155 days post‐booster. Our estimates of protection durations against SARS‐CoV‐2 infection post‐booster vaccination may help inform the ideal frequency of boosters.Keywords
This publication has 53 references indexed in Scilit:
- A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2PLOS Biology, 2021
- Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19Cell Reports Medicine, 2021
- IgA dominates the early neutralizing antibody response to SARS-CoV-2Science Translational Medicine, 2021
- SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predispositionJournal of Clinical Investigation, 2020
- Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 InfectionFrontiers in Immunology, 2020
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityCell, 2020
- Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2British Dental Journal, 2020
- A cross-country database of COVID-19 testingScientific Data, 2020
- Estradiol, Progesterone, Immunomodulation, and COVID-19 OutcomesEndocrinology, 2020
- Influence of Sex on Immunoglobulin LevelsNature, 1967